IPSOGEN announces two studies on Genomic Grade test to be presented at ASCO 2011

IPSOGEN SA (Alternext: ALIPS) today announces that two studies on the Genomic Grade test will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting, that will take place June 3-7, 2011, in Chicago, Ill, USA. The Genomic Grade test (GG), a multi-gene expression test, improves tumor grading, long term prognostication, and consequently treatment decisions for women with early invasive hormone receptor positive breast cancer.

The first study has been run prospectively with a network of 8 Belgian breast cancer centres. The second study, focusing on lobular carcinoma, results from a collaboration with Institut Jules Bordet, and St Luc Hospital, Belgium, and Institut Paoli-Calmettes, France. Both studies, developed in different settings, provide additional evidence for the added value of the Genomic Grade test for tumor grading and, consequently, long term prognosis evaluation.

Poster Presentation: Genomic grade: Feasibility in routine practice and influence on treatment decision in early breast cancer (Abstract #606)

- Lead Author: O. Metzger, Be

- June 6, 1:00 pm to 5:00 pm

- Location: McCormick Place Hall A

Poster Presentation and Discussion: Use of genomic grade index to improve tumor grading of invasive lobular breast carcinoma (Abstract #535)